EISAI INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-04-07
Last Posted Date
2016-12-05
Lead Sponsor
Eisai Inc.
Target Recruit Count
720
Registration Number
NCT00312052
Locations
🇺🇸

Florida Research Network, Gainesville, Florida, United States

🇺🇸

Great Lakes Heart Center of Alpena, Alpena, Michigan, United States

A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-03-31
Last Posted Date
2017-09-14
Lead Sponsor
Eisai Inc.
Target Recruit Count
41
Registration Number
NCT00309179

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-03-24
Last Posted Date
2016-12-05
Lead Sponsor
Eisai Inc.
Target Recruit Count
75
Registration Number
NCT00306735
Locations
🇺🇸

Indiana Blood and Marrow Transplantation, Beech Grove, Indiana, United States

🇺🇸

Cornell Medical Center, New York, New York, United States

🇺🇸

Wake Forest Medical Center, Winston-Salem, North Carolina, United States

and more 7 locations

An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Flexible Bronchoscopy

Phase 3
Completed
Conditions
First Posted Date
2006-03-24
Last Posted Date
2008-11-07
Lead Sponsor
Eisai Inc.
Target Recruit Count
250
Registration Number
NCT00306722
Locations
🇺🇸

Pulmonary Associates of Mobile, PC, Mobile, Alabama, United States

🇺🇸

Saddleback Memorial Medical Center, Laguna Hills, California, United States

🇺🇸

Hurley Medical Center, Flint, Michigan, United States

and more 22 locations

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2006-02-17
Last Posted Date
2011-04-01
Lead Sponsor
Eisai Inc.
Target Recruit Count
821
Registration Number
NCT00293176

A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-02-16
Last Posted Date
2013-05-20
Lead Sponsor
Eisai Inc.
Target Recruit Count
64
Registration Number
NCT00292461
Locations
🇨🇳

National Cheng Kung University Hospital, Tainan, Taiwan, China

🇨🇳

Chang-Gung Memorial Hospital (CGMH), Taipei, Taiwan, China

🇨🇳

Changhua Christian Hospital, Changhua, Taiwan, China

and more 3 locations

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2006-01-26
Last Posted Date
2015-10-28
Lead Sponsor
Eisai Inc.
Target Recruit Count
41
Registration Number
NCT00282399
Locations
🇺🇸

H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

🇺🇸

Albert Einstein College of Medicine, Bronx, New York, United States

🇺🇸

University of Arizona Cancer Center, Tucson, Arizona, United States

Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver

Phase 2
Completed
Conditions
First Posted Date
2006-01-23
Last Posted Date
2010-01-29
Lead Sponsor
Eisai Inc.
Target Recruit Count
192
Registration Number
NCT00280410

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2006-01-23
Last Posted Date
2016-10-07
Lead Sponsor
Eisai Inc.
Target Recruit Count
27
Registration Number
NCT00280397

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-01-19
Last Posted Date
2014-07-14
Lead Sponsor
Eisai Inc.
Target Recruit Count
108
Registration Number
NCT00278993
Locations
🇺🇸

Raleigh Hematology Oncology Associates PL, Raleigh, North Carolina, United States

🇺🇸

Mary Crowley Medical Research Center, Dallas, Texas, United States

🇺🇸

US Oncology, Dallas, Texas, United States

and more 14 locations
© Copyright 2024. All Rights Reserved by MedPath